FDA Approves Genentechs Lucentis (Ranibizumab Injection) for Treatment of Diabetic Retinopathy in People with Diabetic Macular Edema <\/p>\n
On November 14, 2014, a Genentech medicine received FDA approval for use in a specific type of platinum-resistant ovarian cancer. <\/p>\n
On February 6, 2015, the FDA approved a Genentech Medicine for the treatment of diabetic retinopathy in people with diabetic macular edema (DME). <\/p>\n
Presentations, Posters, and Papers galore. Check out our ACR 2014 newsroom to learn more about our commitment to rheumatology. <\/p>\n
Genentech will present important new ophthalmic data at the 118th Annual Meeting of the American Academy of Ophthalmology (AAO) from October 18-21 in Chicago. <\/p>\n
On October 15, 2014, the FDA approved a medicine for the treatment of idiopathic pulmonary fibrosis (IPF). <\/p>\n
Read about Genentechs planned acquisition of Seragon. <\/p>\n
With the recent acquisition of Seragon, Genentech is excited to add a new class of investigational medicines known as SERDs to our pipeline. <\/p>\n
Genentech fully supports efforts to increase transparency around the partnership between the industry and healthcare professionals. <\/p>\n
Medicine for people with chronic idiopathic urticaria (CIU), a form of chronic hives. <\/p>\n
<\/p>\n
Read more here: <\/p>\n
GENE - Genentech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" FDA Approves Genentechs Lucentis (Ranibizumab Injection) for Treatment of Diabetic Retinopathy in People with Diabetic Macular Edema On November 14, 2014, a Genentech medicine received FDA approval for use in a specific type of platinum-resistant ovarian cancer. On February 6, 2015, the FDA approved a Genentech Medicine for the treatment of diabetic retinopathy in people with diabetic macular edema (DME). Continue reading